For the year ending 2025-12-31, VNDA has $488,948K in assets. $161,762K in debts. $84,851K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 84,851 | |||
| Marketable securities | 178,996 | |||
| Accounts receivable, net | 54,578 | |||
| Inventory | 1,852 | |||
| Prepaid expenses and other current assets | 26,985 | |||
| Total current assets | 347,262 | |||
| Property and equipment, net | 2,248 | |||
| Operating lease right-of-use assets | 3,923 | |||
| Finance lease right-of-use assets | 7,343 | |||
| 2026 | 1,463 | |||
| 2027 | 1,463 | |||
| 2028 | 1,463 | |||
| 2029 | 1,463 | |||
| 2030 | 1,463 | |||
| Thereafter | 6,822 | |||
| Hetlioz | 14,137 | |||
| 2026 | 5,544 | |||
| 2027 | 5,544 | |||
| 2028 | 5,544 | |||
| 2029 | 5,544 | |||
| 2030 | 5,544 | |||
| Thereafter | 65,232 | |||
| PONVORY | 92,952 | |||
| 2026 | 941 | |||
| 2027 | 941 | |||
| 2028 | 941 | |||
| 2029 | 941 | |||
| 2030 | 941 | |||
| Thereafter | 5,295 | |||
| Nereus | 10,000 | |||
| Intangible assets, net | 117,089 | |||
| Deferred tax assets | 0 | |||
| Non-current inventory and other | 11,083 | |||
| Total assets | 488,948 | |||
| Accounts payable and accrued liabilities | 68,297 | |||
| Product revenue allowances | 76,865 | |||
| Total current liabilities | 145,162 | |||
| Operating lease non-current liabilities | 2,991 | |||
| Finance lease non-current liabilities | 4,076 | |||
| Other non-current liabilities | 9,533 | |||
| Total liabilities | 161,762 | |||
| Common stock, 0.001 par value 150,000,000 shares authorized 59,101,630 and 58,310,644 shares issued and outstanding at december 31, 2025 and 2024, respectively | 59 | |||
| Additional paid-in capital | 721,264 | |||
| Accumulated other comprehensive income | 629 | |||
| Accumulated deficit | -394,766 | |||
| Total stockholders equity | 327,186 | |||
| Total liabilities and stockholders equity | 488,948 | |||
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)